Abstract
Purpose
Anti-tumor activity can often be enhanced with combination therapy in managing patients with metastatic cancer. However, dose sequence and schedule of delivery can alter the pharmacokinetics, toxicity, and anti-tumor response. Therefore, attention to drug–drug interactions which may be sequence or schedule-dependent are necessary. Docetaxel and topotecan are non-cross-resistance cytotoxic agents with activity in a variety of malignancies. The goal of this study was to determine the maximum tolerated dose of docetaxel and continuous infusion topotecan using two sequences of administration.
Experimental design
Patients were randomized to schedule A or B and enrolled in four escalating-dose cohorts. On schedule A, docetaxel was administered over 1 h and followed by topotecan administered over 72 h. On schedule B, topotecan was given as a 72 h continuous infusion followed by a 1 h infusion of docetaxel. While the doses for the docetaxel and topotecan were the same for schedule A and schedule B, the toxicities, and thus the determination of maximum tolerated dose (MTD), were assessed independently. The plasma pharmacokinetic disposition of topotecan and docetaxel were evaluated during the first cycle of each sequence to assess drug interactions.
Results
Thirty patients, 20 males and 10 females were evaluable for toxicity and response. Four patients were chemonaive. Mean number cycles given were 3. Grade 3/4 thrombocytopenia and neutropenia were comparable on both schedules, as was the dose-limiting toxicity (DLT) for both schedules. There were no apparent differences in absolute neutrophil count or platelet nadirs between schedules A and B for three of the four cohorts. The principal non-hematologic toxicity was nausea and vomiting. The time of overlap of topotecan lactone or total concentrations and docetaxel concentrations were greater on schedule A as compared with schedule B and was associated with reduced clearance of docetaxel on schedule A as compared to schedule B. However, the mean clearance for docetaxel (18∀16 L h−1 m−2 and 29∀28 L h−1 m−2 on schedules A and B, respectively, and topotecan 16∀10 L h−1 m−2 and 7∀6 L h−1 m−2 on schedules A and B, respectively) were not statistically different (P>0.05).
Conclusions
The observed toxicity was not sequence-dependent, despite the observed change in kinetics. Docetaxel and topotecan can be administered with acceptable toxicity at the recommended phase-II dose of docetaxel 60 mg m−2 and topotecan 0.85 mg m−2 day−1×3 days.
Similar content being viewed by others
Abbreviations
- ECOG:
-
Eastern Cooperative Oncology Group
- ULN:
-
Upper limit of normal
- MTD:
-
Maximum tolerated dose
- DLT:
-
Dose-limiting toxicity
- PBS:
-
Phosphate-buffer solution
- AEs:
-
Adverse events
- NLIN:
-
Non-linear
- ROI:
-
Region of interest
- ANC:
-
Absolute neutrophil count
References
Boisdron-Celle M, Gamelin E (2000) Pharmacology of platinum analogs–taxanes interactions. Bull Cancer 87(Spec No):30–33
Clarke SJ, Rivory LP (1999) Related articles, links [abstract] clinical pharmacokinetics of docetaxel. Clin Pharmacokinet 36(2):99–114
D’Argenio DZ, Schmuitzky A (1990) ADAPT II user’s guide: biomedical simulations resource
Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, Van Oosterom AT, Highley M, Guetens G, Mantel M, de Boeck G, de Bruijn E, Verweij J (2002) The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 13(6):583–593
Eisenhauer EA, Vermorken JB (1998) The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 55(1):5–30
Garcia-Carbonero R, Supko JG (2002) Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 8(3):641–661
Grant DS, Williams TL, Zahaczewsky M, Dicker AP (2003) Related articles, links [abstract] comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer 104(1):121–129
Hong WK (2002) The current status of docetaxel in solid tumors. An M.D. Anderson Cancer Center Review. Oncology (Huntingt) 16(6 Suppl 6):9–15
Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11(1):75–81
Kaufmann SH, Peereboom D, Buckwalter CA, Svingen PA, Grochow LB, Donehower RC, Rowinsky EK (1996) Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst 88(11):734–741
Lilenbaum RC, List M, Desch C (1999) Single-agent versus combination chemotherapy in advanced non-small cell lung cancer: a meta-analysis and the Cancer and Leukemia Group B randomized trial. Semin Oncol 26(5 Suppl 15):52–54
Loos WJ, Verweij J, Nooter K et al (1997) Sensitive determination of docetaxel in human plasma by liquid–liquid extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Appl 693:437
Miles D, von Minckwitz G, Seidman AD (2002) Combination versus sequential single-agent therapy in metastatic breast cancer. Oncologist 7(Suppl 6):13–19
Philip PA (2002) Gemcitabine and platinum combinations in pancreatic cancer. Cancer 95(4 Suppl):908–911
Pizzolato JF, Saltz LB (2003) The camptothecins. Lancet 361(9376):2235–2242
Rosing H, Doyle E, Davites BE et al (1997) High-performance liquid chromatographic determination of the novel antitumor drug topotecan and topotecan as the total of the lactone plus carboxylate forms in human plasma. J Chromatogr Biol Biomed Appl 668:107
Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, Le Bail N, Haller DG (2003) Related articles, links [abstract] superiority of oxaliplatin and fluorouracil–leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil–leucovorin: interim results of a phase III trial. J Clin Oncol 21(11):2059–2069
Sederholm C (2002) Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: preliminary findings in a phase III trial of the Swedish Lung Cancer Study Group. Semin Oncol 3(Suppl 9):50–54
Ulukan H, Swaan PW (2002) Camptothecins: a review of their chemotherapeutic potential. Drugs 62(14):2039–2057
Zamboni WC, Egorin MJ, Van Echo DA, Day RS, Meisenberg BR, Brooks SE, Doyle LA, Nemieboka NN, Dobson JM, Tait NS, Tkaczuk KH (2000) Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. J Clin Oncol 18(18):3288–3294
Acknowledgment
Special thanks to Sherron Thornton for manuscript preparation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Posey, J.A., Wang, H., Hamilton, J. et al. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies. Cancer Chemother Pharmacol 56, 182–188 (2005). https://doi.org/10.1007/s00280-004-0925-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-004-0925-8